弥漫型腱鞘巨细胞瘤接受pexidartinib治疗的MRI初步表现
本文报道3例弥漫型腱鞘巨细胞瘤(diffuse TSGCT)患者接受CSF-1抑制剂pexidartinib治疗期间的系列MRI表现。研究描述病灶负荷及信号特征,并与病历记录的疗效进行相关性分析。提示 musculoskeletal 放射科医生需认识这一新型非手术治疗及其治疗中的MRI表现。
要点
- pexidartinib是FDA批准用于症状性弥漫型TSGCT的CSF-1抑制剂,仅通过REMS限制性项目提供。
- MRI是TSGCT诊断和监测的首选影像方法,治疗期间需关注病灶负荷和信号特征变化。
- 放射科医生应了解pexidartinib治疗中弥漫型TSGCT的MRI表现,以准确评估疗效。
关键影像表现/征象
- MRI用于描述弥漫型TSGCT的疾病负荷和信号特征,并与病历记录的疗效进行相关性分析。
临床应用与阅片要点
- musculoskeletal放射科医生应认识pexidartinib这一新型非手术治疗及其治疗中弥漫型TSGCT的MRI表现。
- MRI是TSGCT诊断和监测的首选影像方法,治疗期间应关注病灶负荷和信号特征的变化。
局限性
- 仅3例患者,样本量小。
- 为初步经验,非对照研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Tenosynovial giant cell tumor-diffuse type (diffuse TSGCT) is a benign but locally aggressive proliferative disorder of the synovium. Treatment is usually surgical, although in cases of extensive disease complete synovectomy is not possible and local recurrence rates are high. Pexidartinib (trade name Turalio®), a colony-stimulating factor-1 (CSF-1) inhibitor, was shown in a recent phase III trial to effectively treat diffuse TSGCT and is FDA approved for the treatment of adult patients with symptomatic diffuse TSGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Pexidartinib is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) because of the risk of hepatotoxicity. Magnetic resonance imaging (MRI) is the preferred imaging modality for the diagnosis and surveillance of TSGCT. Here we present three patients with diffuse TSGCT of the knee who underwent multiple MRIs over several years while on pexidartinib. We describe the disease burden and signal characteristics on MRI and correlate with the response reported in the patients' medical records. Given that the use of pexidartinib and other CSF inhibitors is likely to increase, musculoskeletal radiologists should be aware of this novel non-operative treatment and the MRI appearance of diffuse TSGCT during therapy.
引用
- Helming A, Hansford B, Beckett B, et al. Tenosynovial giant cell tumor-diffuse type, treated with a novel colony-stimulating factor inhibitor, pexidartinib: initial experience with MRI findings in three patients. Skeletal Radiol. 2021. PMID: 34586485. doi:10.1007/s00256-021-03924-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。